Release Therapeutics to Present Preclinical Data on Sustained CNS Protein Delivery Platform
Key Points
- Release Therapeutics will present Myo-P4 preclinical findings at the 8th Annual CNS Drug Delivery Summit, December 1–3, 2026, in Boston.
- Its Myo-P encapsulated cell technology uses engineered myoblasts in a pin-sized Myo-Pod device for sustained secretion of therapeutic proteins, demonstrated in vivo for more than 10 months.
- Current programs target rare paediatric CNS disorders: Myo-P4 for metachromatic leukodystrophy and Myo-P5A for Sanfilippo syndrome type IIIA.
Release Therapeutics plans to present new preclinical findings from its Myo-P4 technology at the 8th Annual CNS Drug Delivery Summit, scheduled for December 1–3, 2026, in Boston, Massachusetts. The Swiss biomedical technology company will highlight its proprietary Myo-P encapsulated cell technology (ECT) platform, which is being developed to provide sustained delivery of therapeutic proteins to the central nervous system (CNS).
Release Therapeutics is developing its ECT technology as an approach to addressing challenges associated with delivering therapeutic proteins to the CNS. Sustained delivery strategies are of interest in neurological drug development, where maintaining therapeutic exposure in the brain and surrounding tissues can be difficult.
The upcoming poster presentation will feature data from the company’s Myo-P4 program and provide an overview of the broader therapeutic potential of the platform. The Myo-P® is a modular encapsulated cell technology platform that combines genetically engineered, immortalised human myoblasts capable of sustained secretion of disease-specific therapeutic proteins with the Myo-Pod®, a patented, biocompatible hollow-fibre device no larger than a pin, which has been evaluated following subdural implantation in large-animal models and subcutaneous implantation in clinical studies. Release Tx’s current therapeutic focus is on rare paediatric genetic disorders affecting the CNS, with two programmes in development: the Myo-P4® for metachromatic leukodystrophy (MLD), in collaboration with the Paris Brain Institute, and the Myo-P5A® for Sanfilippo syndrome type IIIA (MPS IIIA), in collaboration with the University of Geneva (UNIGE).
The myoblast cell line has been engineered to produce a range of therapeutic proteins, including antibodies, enzymes and cytokines, with sustained protein secretion demonstrated in vivo for more than 10 months. Myo-Pod device is cargo-agnostic, while the broader ECT has been evaluated following subdural, subcutaneous and peritumoural implantation, supporting its potential application across multiple therapeutic areas.
For more information, visit: www.release-tx.com.
Total Page Views: 12
